Treatment of resistance to pirfenidone

Pirfenidone (Pirfenidone) is a drug used to treat idiopathic pulmonary fibrosis. If the patient develops resistance to pirfenidone, increasing the drug dose may be considered to improve the efficacy. However, dose adjustments should be made under the guidance of a physician and patient response and tolerability need to be monitored. Since everyone's physique is different and their resistance to drugs is also different, please inform your doctor in time if you feel unwell.

The combined use of other anti-fibrotic drugs may increase the therapeutic effect. For example, the combination with other anti-fibrotic drugs such as cytosine may have a synergistic effect to further reduce symptoms and delay disease progression. It is important to regularly monitor disease progression and drug efficacy in patients receiving pirfenidone. Through regular examination of lung function, imaging evaluation and clinical evaluation, drug resistance can be detected early and treatment options can be adjusted. In addition to drug treatment, other supportive treatment measures, such as exercise, nutritional adjustment, oxygen therapy, etc., can also be combined to improve patients' symptoms and quality of life.

Pirfenidone has been approved for marketing in China under the trade name of Asri. It has entered the scope of Class B medical insurance and is limited to patients with idiopathic pulmonary fibrosis. The specifications produced by domestic pharmaceutical factoriesThe price of 100mg*54 capsules per box is around RMB 500. There are also generic pirfenidone drugs produced in other countries overseas. For example, the price of a box of 200mg*30 tablets produced by an Indian pharmaceutical factory is around RMB 100 (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.